KURA ONCOLOGY, INC. Increase (Decrease) in Contract with Customer, Liability
KURA ONCOLOGY, INC. (KURA) reported Increase (Decrease) in Contract with Customer, Liability of -$19.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-12
- KURA ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$10.36M.
- KURA ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$9.44M, a 127.30% decline year-over-year.
- KURA ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $156.29M.
- KURA ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $15.66M.
- KURA ONCOLOGY, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $195.72M, a 29.64% decline from fiscal 2024.
- KURA ONCOLOGY, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $278.18M.
- KURA ONCOLOGY, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$19.81M 10-Q · filed 2026-08-12 | $136.48M derived: sum of 3 quarters · filed 2026-08-12 | $152.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$9.44M 10-Q · filed 2026-05-12 | $146.84M derived: sum of 2 quarters · filed 2026-05-12 | $162.51M derived: sum of 3 quarters · filed 2026-05-12 | $151.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $156.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $171.95M derived: sum of 2 quarters · filed 2026-03-05 | $161.12M derived: sum of 3 quarters · filed 2026-08-12 | $195.72M 10-K · filed 2026-03-05 |
| 2025-09-30 | $15.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.83M derived: sum of 2 quarters · filed 2026-08-12 | $39.43M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | -$10.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $23.76M 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $34.59M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $278.18M 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |